Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Drug Alcohol Depend. 2019 Aug 24;204:107501. doi: 10.1016/j.drugalcdep.2019.06.006

Figure 3.

Figure 3.

Effectiveness of 0.01 mg/kg/h naltrexone (NTX) alone or in combination with the active heroin vaccine on the antinociceptive potency of subcutaneous (SC) or intravenous (IV) heroin in male and female rats. Panel A shows cumulative SC heroin dose-effect functions at baseline (BL) and during 0.01 mg/kg/h naltrexone alone or 0.01 mg/kg/h naltrexone plus active vaccine (week 9). Panel B shows corresponding individual and group mean potency shifts compared to BL. Panel C shows cumulative IV heroin dose-effect functions at BL and during 0.01 mg/kg/h naltrexone alone or 0.01 mg/kg/h naltrexone plus active vaccine (week 11). Panel D shows corresponding individual and group mean potency shifts compared to BL. Abscissae: cumulative drug dose (mg/kg, SC or IV) (Panels A and C) or treatment condition (Panels B and D). Ordinate: percent maximum possible effect (Panels A and C) or potency ratios (Panels B and D). Asterisk indicates statistical significance (p<0.05) compare to naltrexone alone. All points in panels A and C and bars in panels B and D represent mean ± s.e.m. of 5–6 rats.